Overview:
With
the FDA’s Quality Management System Regulation (QMSR) taking effect in February
2026, medical device manufacturers are entering one of the most significant
quality-system shifts in decades. The replacement of the long-standing Quality
System Regulation (QSR) with a framework that integrates ISO 13485 into 21 CFR
Part 820 is not a simple regulatory update—it represents a fundamental change
in how quality systems are expected to function.
This
course provides a practical explanation of what the QMSR is, why it matters,
and how it reshapes FDA expectations. While the new regulation aligns U.S.
requirements more closely with ISO 13485, it also retains key FDA-specific
provisions and introduces a stronger emphasis on risk-based thinking across all
Quality System processes. Organizations that view compliance as a documentation
exercise will find that approach insufficient under QMSR. The focus has shifted
decisively from “what documents exist” to how well processes control quality
and risk.
A
central pillar of QMSR is the application of risk evaluation to Quality System
processes, not just to product design. However, the regulation itself does not
prescribe how manufacturers should perform this analysis. This session bridges
that gap by explaining the Hazard Analysis approach aligned with ISO 14971 and
demonstrating how it can be applied meaningfully to core QS processes such as
supplier control, CAPA, change control, and training.
The
webinar also addresses two areas where FDA expectations have become notably
stronger: top management involvement and supplier oversight. Senior leadership
is now expected to play an active, accountable role in the Quality System, and
supplier controls must be demonstrably risk-based and robust. Attendees will
gain clarity on what FDA investigators are likely to look for during
inspections and where organizations commonly fall short during transitions to
new regulatory frameworks.
By the end of this session, participants will have a clearer understanding of how QMSR changes the definition of “quality,” what practical adjustments may be needed within their existing systems, and why conformance to ISO 13485 alone is no longer enough without integrated, risk-based quality processes.
Areas
covered in the session:
- ISO
13485
- QMSR
requirements
- Retained
sections of 21 CFR 820
- Hazard
analysis procedure
- How to apply risk analysis to QS processes
- FDA
inspections
Why
should you attend?
If
you’re responsible for quality, regulatory, or compliance in a medical device
organization, the FDA’s QMSR effective February 2026 is not a change you can
“absorb later.” It reshapes how FDA expectations align with ISO 13485 while
retaining important FDA-specific elements, and it raises the bar on how your
quality system is expected to function—not just what documents you maintain.
This
session will help you clearly understand what is changing from QSR to QMSR,
what is being retained, and where organizations are most likely to misjudge the
transition. You’ll also get a practical explanation of how risk evaluation is
expected to be applied to quality system processes—something the rule
emphasizes, but doesn’t spell out step-by-step.
If
your current approach leans heavily on documentation rather than risk-based,
integrated processes, this webinar will help you refocus on what “good” will
look like in a QMSR world.
Handouts:
Attendees
will receive exclusive handouts, including the speaker’s presentation materials
plus Amorit Education resources such as a QSR → QMSR Transition Comparison Matrix and an
ISO 14971-aligned Hazard Analysis-to-QS Processes handout to help teams
translate the session into practical next steps.
Who
will benefit?
This
webinar is designed for professionals involved in quality, regulatory,
compliance, and operational oversight within medical device organizations.
Those include:
- Quality
Assurance Manager
- Quality
Systems Manager
- Quality
Engineer
- Quality
Compliance Specialist
- Regulatory
Affairs Manager
- Regulatory
Affairs Specialist
- Compliance
Manager
- Internal
Auditor
- Lead
Auditor
- Supplier
Quality Engineer
- Supplier
Quality Manager
- CAPA
Coordinator
- Change
Control Coordinator
- Document
Control Specialist
- Training
Coordinator
- Manufacturing/Operations
Manager
- Process
Engineer
Edwin
Waldbusser is a consultant retired from industry after 20 years in management
of development of medical devices (5 patents). He has been consulting in the US
and internationally in the areas of design control, risk analysis and software
validation for the past 11 years.
Mr. Waldbusser has a BS in Mechanical Engineering and an MBA. He is a Lloyds of London certified ISO 9000 Lead Auditor and a member of the Thomson Reuters Expert Witness network.
Enrollment Options
Tags: Medical Devices, FDA Compliance, QMSR, QSR, ISO 13485, ISO 14971, Quality Assurance, Quality Systems, Regulatory Affairs, Risk Management, Supplier Quality, CAPA, Change Control, Training & Competency, FDA Inspection Readiness, Edwin Waldbusser, January 2026, Webinar

